Browsing by Author "Kilickap, Saadettin"
Now showing items 1-20 of 23
-
Antibody responses to COVID-19 vaccination in cancer: a systematic review
Guven, Deniz Can; Sahin, Taha Koray; Kilickap, Saadettin; Uckun, Fatih M. (Frontiers Media SA, 2021)Introduction: After the results of phase III vaccine studies became available, the leading oncology societies recommended two doses of COVID-19 vaccination to all patients with cancer with no specific recommendation for ... -
The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors
Guven, Deniz Can; Aktepe, Oktay Halit; Aksun, Melek Seren; Sahin , Taha Koray; Kavgaci, Gozde; Ucgul, Enes; Cakir, Ibrahim Yahya; Yildirim, Hasan Cagri; Guner, Gurkan; Akin, Serkan; Kertmen, Neyran; Dizdar, Omer; Aksoy, Sercan; Erman, Mustafa; Suayib, Yalcin; Kilickap, Saadettin (IOS Press, 2022)BACKGROUND: The albumin-globulin ratio (AGR) could be a prognostic biomarker in patients with cancer, although the data is limited in patients treated with immune-checkpoint inhibitors (ICIs). OBJECTIVES: We aimed to ... -
The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study
Guven, Deniz Can; Acar, Ramazan; Yekedüz, Emre; Bilgetekin, İrem; Baytemur, Naziyet Kose; Erol, Cihan; Ceylan, Furkan Sacit; Kılıçkap, Saadettin (Mosby Inc., 2021)Background: Immunotherapy improves overall survival (OS) in the second and later lines of renal cell carcinoma (RCC) treatment. Recent studies have suggested that antibiotic (ATB) use either shortly before or after the ... -
The association between early changes in neutrophil-lymphocyte ratio and survival in patients treated with immunotherapy
Guven, Deniz Can; Sahin, Taha Koray; Erul, Enes; Cakir, Ibrahim Yahya; Ucgul, Enes; Yildirim, Hasan Cagri; Aktepe, Oktay Halit; Erman, Mustafa; Kilickap, Saadettin; Aksoy, Sercan; Yalcin, Suayib (MDPI, 2022)Dynamic changes in the blood-based biomarkers could be used as a prognostic biomarker in patients treated with immune checkpoint inhibitors (ICIs), although the data are limited. We evaluated the association between the ... -
The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A systematic review and meta-analysis
Guven, Deniz Can; Sahin, Taha Koray; Erul, Enes; Kilickap, Saadettin; Gambichler, Thilo; Aksoy, Sercan (PMC, 2022)Background: Prognostic scores derived from the blood count have garnered significant interest as an indirect measure of the inflammatory pressure in cancer. The recently developed pan-immune-inflammation value (PIV), an ... -
The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme
Güven, Deniz Can; Aksun, Melek Seren; Çakır, İbrahim Yahya; Kılıçkap, Saadettin; Kertmen, Neyran (2021)Background: The association between obesity and sarcopenia (via temporal muscle thickness) with overall survival (OS) has been evaluated in several glioblastoma multiforme studies, however, the data are inconclusive. ... -
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: A real-life data of the Turkish Oncology Group
Gurbuz, Mustafa; Kutlu, Yasin; Akkus, Erman; Koksoy, Elif Berna; Kose, Naziyet; Oven, Bala Basak; Uluc, Basak Oyan; Demiray, Atike Gokcen; Erdem, Dilek; Demir, Bilgin; Turhal, Nazım Serdar; Uskent, Necdet; Akbas, Sinem; Selcukbiricik, Fatih; Inal, Ali; Bilici, Ahmet; Kilickap, Saadettin (Springer, 2022)Purpose Atezolizumab has been shown to be efective and safe in randomized trial in the frst-line treatment of extensivestage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this ... -
The benefit of treatment beyond progression with immune checkpoint inhibitors: A multi-center retrospective cohort study
Guven, Deniz Can; Yekeduz, Emre; Erul, Enes; Coskun Yazgan, Sati; Sahin, Taha Koray; Karatas, Gokturk; Aksoy, Sercan; Erman, Mustafa; Yalcin, Suayib; Urun, Yuksel; Kilickap, Saadettin (Springer, 2022)Objective: Treatment beyond progression (TBP) with immune checkpoint inhibitors (ICIs) is an evolving field due to the limitations of conventional imaging in response evaluation. However, real-life data on the benefit of ... -
Blood based biomarkers as predictive factors for hyperprogressive disease
Yildirim, Hasan Cagri; Guven, Deniz Can; Aktepe, Oktay Halit; Taban, Hakan; Yilmaz, Feride; Yasar, Serkan; Aksoy, Sercan; Erman, Mustafa; Kilickap, Saadettin; Yalcin, Suayib (MDPI, 2022)Purpose: With the widespread use of immunotherapy agents, we encounter treatment responses such as hyperprogression disease (HPD) that we have not seen with previous standard chemotherapy and targeted therapies. It is known ... -
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study
Yekeduz, Emre; Ozbay, Mehmet Fatih; Caglayan, Dilek; Yildirim, Atila; Erol, Cihan; Yildirim, Hasan Cagri; Tunc, Sezai; Ozyurt, Neslihan; Ozdemir, Feyyaz; Sendur, Mehmet Ali Nahit; Kilickap, Saadettin (LIPPINCOTT WILLIAMS & WILKINS, 2022)Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study -
Differences between hyperprogressive disease and progressive disease in patients receiving immunotherapy
Yildirim, Hasan Cagri; Guven, Deniz Can; Aktepe, Oktay Halit; Taban, Hakan; Yilmaz, Feride; Yasar, Serkan; Aktas, Burak Yasin; Guner, Gurkan; Dizdar, Omer; Aksoy, Sercan; Erman, Mustafa; Yalcin, Suayib; Kilickap, Saadettin (Kare Publishing, 2022)Objectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter ... -
External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database
Yekeduz, Emre; Karakaya, Serdar; Erturk, Ismail; Tural, Deniz; Ucar, Gokhan; Oztas, Nihan Senturk; Ozguroglu, Mustafa; Kucukarda, Ahmet; Sever, Ozlem Nuray; Kilickap, Saadettin; Oksuzoglu, Berna; Demirci, Umut; Arikan, Nuriye (Elsevier, 2022)Background: A novel prognostic model was recommended for patients with metastatic RCC (mRCC) by the International mRCC Database Consortium (IMDC). In this study, we aimed to externally validate a novel risk model for the ... -
Lower prognostic nutritional index is associated with poorer survival in patients receiving ımmune-checkpoint ınhibitors
Guven, Deniz C.; Aktepe, Oktay H.; Taban, Hakan; Aktas, Burak Y.; Guner, Gurkan; Yildirim, Hasan C.; Kilickap, Saadettin (Future Medicine, 2021)Aim: Blood-based biomarkers like prognostic nutritional index (PNI) are readily available biomarkers for immunotherapy efficacy, although the data are limited. So, we aimed to evaluate the association between PNI and overall ... -
Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality
Guven, Deniz Can; Sahin, Taha Koray; Yildirim, Hasan Cagri; Cesmeci, Engin; Gulbahce Incesu, Fatima Gul; Kilickap, Saadettin (BMJ, 2021)Background: We compared the new outpatient clinic referrals during the first 10 months of the COVID-19 pandemic with the year before. Methods: We compared baseline characteristics of the 2208 new referrals in 2020 (n=922) ... -
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database
Yekeduz, Emre; Erturk, Ismail; Tural, Deniz; Karadurmus, Nuri; Karakaya, Serdar; Kilickap, Saadettin (Future Medicine, 2021)Aim: The authors present real-world data on the efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Methods: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database includes ... -
Pazopanib-induced chylothorax in a patient with renal cell carcinoma
Koylu, Bahadir; Tekin, Fatih; Aktas, Burak Yasin; Kilickap, Saadettin; Koksal, Deniz (Wolters Kluwer, 2022)Pazopanib is an oral multi-kinase inhibitor approved for the treatment of advanced renal cell carcinoma (RCC). It is an anti-angiogenic agent, which blocks the activation signaling pathways of tyrosine kinases and prevents ... -
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)
Kilickap, Saadettin; Paksoy, Nil; Bilgin, Burak; Sakin, Abdullah; Ozcan, Erkan; Tatli , Ali Murat; Hizal, Mutlu; Paksoy, Nail; Kahraman, Sedat (Springer, 2022)Introduction: Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that the percentage ... -
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab
Tural, Deniz; Olmez, Omer Fatih; Sumbul, ahmet Taner; Ozhan, Nail; Cakar, Burcu; Paksoy Turkoz, Fatma; Kilickap, Saadettin (Springer, 2021)Background: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies of patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of Atezolizumab ... -
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, alk-positive non-small-cell lung cancer patients: A turkish oncology group study
Hizal, Mutlu; Bilgin, Burak; Paksoy, Nail; Kilickap, Saadettin; Atci, Muhammed Mustafa; Kahraman, Seda; Ayhan, Murat; Tural, Deniz; Yaman, Sebnem; Kutlu, Yasin; Korkmaz, Mustafa; Aksoy, Asude; Arak, Hacı; Korkmaz, Taner; Ak, Naziye; Akdeniz, Nadiye; Sakin, Abdullah; Fulden Yumuk, Perran (Atypon, 2022)Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell ...
